Principal Investigators
Publications
Principal Investigator: Felicia Cosman
Study: An Evaluation of Quantitative Computed Tomography (pQCT) to measure bone after treatment with parathyroid hormone. In this study the SCANCO pQCT machine (XtremeCT, SCANCO Medical AG, Basserdorf, Switzerland) will be used to measure bone mineral density, size and structure of the arm and leg. The objective of this investigation is to determine cross sectional differences in bone size, volumetric differences and structure at the end of treatment with parathyroid hormone.
Principal Investigator: Robert Lindsay
Study: Mechanism of anabolic action of 1-34hPTH in women treated with risedronate for osteoporosis. In this study we will examine the mechanisms of PTH effects, as a single therapy and in combination with prior and ongoing risedronate, when given daily continuously or in 3 month cycles, utilizing histomorphometry following our unique tetracycline labeling regimen.
Principal Investigator: Jeri W. Nieves
Study: Global Longitudinal Registry of Osteoporosis in Women (GLOW). The goal of this research is to improve our understanding of the risk and prevention of osteoporosis-related fractures among female residents who are 55 years of age and older. The full study is multinational and will involve subjects from nine countries in 14 different locations, including Helen Hayes Hospital.
Principal Investigator: Felicia Cosman
Study: The objective is to demonstrate that combination therapy with once yearly IV Zoledronic acid and daily subcutaneous injections of teriparatide is similar to teriparatide treatment alone or zoledronic acid alone with respect to lumbar spine BMD.
Principal Investigator: Felicia Cosman
Study: The aim of this study is to determine if 1-year administration of an experimental drug given to postmenopausal women with osteopenia results in a significant increase in BMD at doses that are safe and well tolerated.
Principal Investigator: Felicia Cosman:
Study: The objective of this study is to evaluate the effect of denosumab compared to alendronate sodium after 12 months in postmenopausal women.
Principal Investigator: Robert Lindsay
Study: Bone density quality control is monitored and assured by the Bone Quality Control Center (BQCC) within the Clinical Research Center.
Principal Investigator: Robert Lindsay
Study: Mechanism of Anabolic Action of PTH with and without Alendronate.
The major hypothesis addressed in this protocol is that recombinant human PTH1-34 (referred to here as PTH), when given as a daily subcutaneous injection (20mcg/day), acts in two distinct phases: the early direct anabolic phase and a later remodeling- based anabolic phase. We further postulate that these differing skeletal responses can be modulated when PTH is given in a cyclical fashion and each response will also be modified in different ways by the presence of a potent antiresorptive agent (alendronate).
Principal Investigator: Jeri Nieves
Study: The New York State Osteoporosis Prevention and Education Program (NYSOPEP). NYSOPEP continues to educate New York residents, with Helen Hayes Hospital also serving as a Regional Center for this statewide effort. The goal of this program is to educate health professionals and the public about osteoporosis and how to prevent this disease. Helen Hayes Hospital staff maintain our website www.nysopep.org and provide numerous educational seminars.
Principal Investigator: Jeri Nieves
Study: An Evaluation of 3 Dimensional Hip Measurements by DXA to measure structural properties of the femur after treatment with parathyroid hormone
The objective of this investigation is to determine differences in bone size, shape and structure of the hip by DXA at the beginning and end of treatment with parathyroid hormone. We will also determine how 3D hip DXA measurements compare with standard bone mineral density, with QCT assessments and with bone biopsy results. |
